A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Exclusion Criteria

• •Clinical evidence of acutely infected pyoderma gangrenosum
• •History of allergic or anaphylactic reactions to monoclonal antibodies
• •History of recurrent or chronic systemic infections
• •Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding